EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY 4.0

Serology as an early diagnostic tool in pediatric patients with Shiga toxin-producing Escherichia coli -associated hemolytic uremic syndrome: a post hoc analysis of a phase 2 clinical trial

Stella M Landivar, Luciano J Melli, Mariana Pichel, Marta Rivas, Mariana Colonna, Carolina Massa, Vanesa Zylberman, Santiago Sanguineti, Linus Spatz, Fernando Goldbaum, Diego J Comerci, Juan E Ugalde iD und 2 weitere

Journal of Clinical Microbiology · 2026

DOI: 10.1128/jcm.01415-25 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Microbiology, 2026. Verfasst von Stella M Landivar und 13 weiteren Autor:innen. Beteiligte Einrichtung: Instituto de Investigaciones Biotecnológicas, Universidad Nacional de San Martín (UNSAM)-Consejo Nacional de Investigaciones Científicas y Técnicas (…. Hauptthemen laut MEDLINE: Antibodies, Bacterial, Escherichia coli Infections, Hemolytic-Uremic Syndrome, Serologic Tests. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agencia Nacional de Promoción Científica y Tecnológica.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The specific anti-O polysaccharide antibody response in Shiga toxin-producing Escherichia coli -associated hemolytic uremic syndrome (STEC-HUS) patients and its relevance for early diagnosis have not been previously studied in detail. In this pre-planned post hoc analysis, we evaluated the IgM/IgG antibody response in 55 patients monitored since the date of clinical STEC-HUS diagnosis. Four serum samples per patient were collected at 12–24 h (T1), 48 h after T1, and 7 and 28 days post-STEC-HUS diagnosis. The serogroup-specific anti-O polysaccharide antibody response was evaluated by the glycoprotein-based assays. E. coli O157, O145, O121, O103, O111, O26, and O45 Glyco-iELISAs and the lateral flow immunoassay (LFIA) CHEMSTRIP E. coli O157/O145 and three IgM/IgG response patterns were observed. Analysis of the serum samples at T1 by Glyco-iELISAs and the LFIA revealed an overall reactivity of 89.1% (49/55), a value significantly higher than those obtained by stx /Stx detection (74%, 37/50) and stool culture (16.3%, 9/55). When combining all methodologies, the association with STEC infection was 96.4% (53/55). In samples ranging from 2 to 5 days post-diarrhea onset, the reactivity by serology, stx /Stx detection, and stool culture was 77.8%, 73.1%, and 25.9%, respectively, but when combining all the methodologies, it increased to 92.6%. The detection of serogroup-specific anti-O polysaccharide antibodies alone or in combination with fecal diagnostics significantly contributed to STEC diagnosis in HUS patients, even very early in the course of the infection. These findings strongly support the incorporation of serology into diagnostic algorithms for timely diagnosis and proper management of STEC-HUS patients. IMPORTANCE This study evaluated, for the first time, the dynamics of serogroup-specific IgM and IgG anti-O polysaccharide antibody response in 55 Shiga toxin-producing Escherichia coli -associated hemolytic uremic syndrome (STEC-HUS) pediatric patients. We provide evidence that the detection of serogroup-specific anti-O polysaccharide antibodies alone or in combination with bacterial isolation and/or stx/Stx detection from stool samples significantly contributes to STEC diagnosis in HUS patients in the first days after the onset of diarrhea. This could potentially improve the way we currently diagnose these infections. Our glycoprotein-based serological tests could be incorporated into diagnostic algorithms and implemented in primary care settings upon presentation of bloody or non-bloody diarrhea, enabling rapid and simple screening without the need for invasive procedures. This could allow the timely identification of these potentially harmful infections and close monitoring of these patients or help refer them to tertiary-care hospitals for proper clinical management. CLINICAL TRIALS This study was registered with ClinicalTrials.gov as NCT05569746 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BacterialEscherichia coli InfectionsHemolytic-Uremic SyndromeSerologic TestsShiga-Toxigenic Escherichia coliChildChild, PreschoolFemaleHumansInfantMaleEarly DiagnosisImmunoglobulin GImmunoglobulin MO Antigens

Stichwörter der Autor:innen

ELISALFIASTECdiagnosticglycoproteinhemolytic uremic syndromephase 2 clinical trialserodiagnosis

Substanzen

Antibodies, BacterialImmunoglobulin GImmunoglobulin MO Antigens

Autor:innen und Institutionen

  • Instituto de Investigaciones Biotecnológicas, Universidad Nacional de San Martín (UNSAM)-Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Escuela de Bio y Nanotecnologías (EByN), Universidad Naciona…
  • Inmunova S. A., San Martín, Argentina.

ORCID-Profile: Juan E Ugalde, Andrés E Ciocchini

Förderung

  • Agencia Nacional de Promoción Científica y Tecnológica

Zitieren

APA

Landivar, S. M., Melli, L. J., Pichel, M., Rivas, M., Colonna, M., Massa, C., Zylberman, V., Sanguineti, S., Spatz, L., Goldbaum, F., Comerci, D. J., Ugalde, J. E., Ciocchini, A. E., & INM004 Study Group (2026). Serology as an early diagnostic tool in pediatric patients with Shiga toxin-producing Escherichia coli -associated hemolytic uremic syndrome: a post hoc analysis of a phase 2 clinical trial. Journal of Clinical Microbiology. https://doi.org/10.1128/jcm.01415-25

Vancouver

Landivar SM, Melli LJ, Pichel M, Rivas M, Colonna M, Massa C, et al. Serology as an early diagnostic tool in pediatric patients with Shiga toxin-producing Escherichia coli -associated hemolytic uremic syndrome: a post hoc analysis of a phase 2 clinical trial. Journal of Clinical Microbiology. 2026. doi:10.1128/jcm.01415-25

BibTeX
@article{Landivar2026,
  author = {Landivar, Stella M and Melli, Luciano J and Pichel, Mariana and Rivas, Marta and Colonna, Mariana and Massa, Carolina and Zylberman, Vanesa and Sanguineti, Santiago and Spatz, Linus and Goldbaum, Fernando and Comerci, Diego J and Ugalde, Juan E and Ciocchini, Andrés E and INM004 Study Group, INM004 Study Group},
  title = {Serology as an early diagnostic tool in pediatric patients with Shiga toxin-producing Escherichia coli -associated hemolytic uremic syndrome: a post hoc analysis of a phase 2 clinical trial},
  journal = {Journal of Clinical Microbiology},
  year = {2026},
  doi = {10.1128/jcm.01415-25}
}
Kostenlos starten →